Inventiva S.A. (EPA:IVA)
5.70
-0.04 (-0.70%)
At close: Jan 28, 2026
Inventiva Revenue
Inventiva had revenue of 2.81M EUR in the half year ending June 30, 2025, with 105.19% growth. This brings the company's revenue in the last twelve months to 13.61M, down -12.84% year-over-year. In the year 2024, Inventiva had annual revenue of 14.72M, down -36.43%.
Revenue (ttm)
13.61M
Revenue Growth
-12.84%
P/S Ratio
64.62
Revenue / Employee
202.02K
Employees
118
Market Cap
1.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | 512.36K | 5.42% |
| Dec 31, 2016 | 9.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 179.91M |
| Cellectis | 70.36M |
| Genfit | 45.13M |
| MedinCell | 32.44M |
| Adocia | 12.88M |
| Innate Pharma | 12.64M |
| Nanobiotix | 10.16M |
| Transgene | 7.58M |
Inventiva News
- 9 hours ago - Biotech Inventiva's 50% surge shows investor optimism over liver disease drug - Reuters
- 9 hours ago - Inventiva (IVA) Receives Overweight Rating as Barclays Initiates Coverage | IVA Stock News - GuruFocus
- 13 days ago - Inventiva SA at JPMorgan Healthcare Conference Transcript - GuruFocus
- 13 days ago - Inventiva S.A. (IVA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 13 days ago - Inventiva S.A. (IVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Inventiva (IVA) Initiates Coverage with "Outperform" Rating by Leerink Partners | IVA ... - GuruFocus
- 20 days ago - Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know - Nasdaq
- 2 months ago - Inventiva S.A. reports nine-months results - Seeking Alpha